ImmuneOnco started Phase Ib/II Clinical Study of IMM01: An IMM01 combined with azacitidine clinical trial completed the first patient enrollment and dosing

On June 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that SIRPaFc recombinant protein targeting human CD47 ，IMM01， combined with azacitidine (AZA) in the treatment of relapsed ......

2022-06-28

ImmuneOnco submitted application of investigating new drug (IND) IMM40H for clinical research application to the National Medical Products Administration (NMPA)

On June 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that application of investigating new drug (IND) IMM40H for clinical research to the National Medical Products Administ......

2022-06-24

Phase I clinical trial of IMM2902 completed the first patient enrollment and dosing in the United States.

On June 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that, on June 20, local time, an FDA-registered Phase I clinical trial of the first globally novel bi-specific antibody-rec......

2022-06-21

IMM2902 Invention Patent was Authorized by the US Patent Office

On June 16, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the first bispecific antibody-receptor recombinant protein targeting human CD47 x HER2 (IMM2902), authorized by the United States Pate......

2022-06-16

ImmuneOnco’s IMM27M，an ADCC-enhanced CTLA-4 antibody completed the first patient enrollment and dosing

On June 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that our newly developed ADCC-enhanced CTLA-4 antibody (IMM27M) completed the first patient enrollment and first dosing. The administration......

2022-06-15